| ||||||||||||||||||
| ||||||||||||||||||
| acetaminophen elixir |
Weight loss pills - Lose weight with minimum effort Posted By : Smartess Chikwendu Weight loss pills refer to prescribed tablets that will help reduce the weight of an individual. These days, in the US, there is a lot of importance attached towards loss of weight. Obesity is one of the major problems plaguing people of all age groups owing to a variety of reasons. They could be sedentary life style, lack of exercise, diet rich in fats and carbohydrates and uncontrolled consumption of junk food. In some states, obesity has taken the form of a disease with entire families appearing over weight. By: Smartess Chikwendu Article Directory: http://www.articledashboard.com
Smartress Chikwendu is the author of this article on Weight Loss Pill. Know Useful tips to Weight Loss at Weightpruners.com
generic drug for ambien, dur e du film spiderman 3, canine loratadine, paxil headaches, prilosec otc and gallbladder pain, ritalin bad experiences, sertraline generic teva, tramadol how supplied, best discount free viagra via, xenical facts 16:45 - 2008-Mar-31 - comments {0} - post commentAre Cold Sores Contagious?When someone suffers from a cold sore, the first thought that could arise in your mind is whether you can catch the same infection from that person.The cold sores can spread easily from one to the other in more than one way. You can infect others easily through your cold sore. It is spread through a virus, which is easily spreadable. A person does not have an active cold sore but posses the virus herpes simplex virus. As it is commonly, said HSV-1 virus that causes cold sore generally affects at the age five. It will show its ill effects in form of cold sore after puberty. This virus can lie in an inactive form for a longer time and transfers in to a disease named cold sore. Cold sore is a highly contagious disease. You have to avoid kissing, coughing, sneezing and through a common touch of the infected person. Other people get easily affected. These viruses are easily transferable. A child can get cold sore through touch of infected parent in a daily routine. It is sensitive disease and spread by common touch. One of the most common ways that HSV-1 spread is through a used thing of an infected person, could be a toothbrush or tube of lip balm. There is a strong risk of infection to the next person if particles of the HSV-1 virus transferred to an object and someone else uses it. Thus the contamination of disease occurs. People are most possible to become infected with this virus by coming into contact to someone with a cold sore. Here chances of getting the infection are very high.Cold sore developes in many stages or steps before it goes away. The tingle stage is the first where the virus gets out of sleep. At this point, the cold sore has not yet formed, but the virus get reactivated. The next stage is weeping stage. In the weeping stage of cold sore, the risk of spreading the virus increases and becomes high risky. At this stage, the sore burst opens and expels a clear liquid. The risk of infection is greater than normal in the crusting stage when the sore scabbed over. These are the stages and possibilities of being infected by cold sore. In every stage, they are contagious. You have to make sure that the other person will not be in danger because of you. Avoid close contact by any way to the other person if you have cold core. You will never think that are core cores contagious. Take care of your hygiene. It is beneficial to remark that HVS-1 virus not only easily spread able among people but also flexible to transfer within different parts of body. The infected person may harm himself by affecting various parts of body.People must be sure to wash their hands systematically when they have a cold sore to avoid the spread of HSV-1. Just avoid contact to the infected person and save yourself from cold sore infection. Muna wa Wanjiru Has Been Researching and Reporting on Cold Sores for Years. For More Information on Are Cold Sores Contagious, Visit His Site at ARE COLD SORES CONTAGIOUSI Will Also Highly Appreciate Your Views On Are Cold Sores Contagious At My Blog here ? ? Are Cold Sores Contagious
ambien librement, phentermine is an amphetamine, ativan hydrocodone, azmacort mdi, diazepam description, meclizine causing low potassium, taking yourself off of paxil, sildenafil citrate kamagra, detcting vicodin in blood urine, rebate zyrtec 20:12 - 2008-Mar-30 - comments {0} - post commentSomaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of InsomniaSomaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SILENOR(TM) (doxepin hydrochloride). Somaxon is seeking marketing approval of SILENOR(TM) for the treatment of insomnia. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, the FDA is expected to determine whether to accept the NDA for filing within 60 days, and to notify the company of its determination within fourteen days thereafter. If the NDA is accepted for filing, under the PDUFA guidelines it is expected that the FDA will complete its review and provide an action letter with respect to the NDA within 10 months following submission of the NDA, or in December 2008. "The completion and submission of our NDA for SILENOR™ represents a significant milestone for Somaxon," said David F. Hale, Somaxon's executive chairman and interim chief executive officer. "It is the culmination of a thorough development program that includes six well controlled clinical trials, all of which met their primary endpoints, and multiple non-clinical studies. We believe that the improvements in sleep onset, sleep maintenance and sleep duration and the favorable safety and tolerability profile demonstrated by our clinical development program are sufficient to support a determination by the FDA that SILENOR™ can be approved for the treatment of insomnia. I would like to thank the team at Somaxon, as well as the many clinicians and experts who worked with us, for their efforts in the design and conduct of the SILENOR™ development program and the preparation of this NDA for submission." "Insomnia is a significant health concern in the United States. Millions of people are affected, many of whom remain undiagnosed and untreated by a physician," said Tom Roth, Ph.D., chief, division head, Sleep Disorders & Research Center, Henry Ford Hospital. "There is mounting evidence that untreated insomnia can lead to significant health consequences, including an increased risk of depression, obesity and cardiovascular disorders. If SILENOR™ is approved by the FDA, it has the potential to provide clinicians and patients with a unique treatment option for insomnia." Andrew Krystal, M.D., associate professor with tenure, Duke University School of Medicine and Director, Sleep Research Laboratory and Insomnia Program, Duke University, added, "Pharmacologically, low dose doxepin, the active ingredient in SILENOR™, is unique. It is thought that SILENOR™ improves sleep by selectively blocking the wake-promoting neurotransmitter histamine, thereby decreasing the drive for wakefulness. This novel mechanism of action most likely explains the significant improvement in insomnia symptoms that was observed in controlled clinical trials without adverse effects such as amnesia, complex sleep behaviors or physical or psychological dependence." About the SILENOR™ NDA and Background of the Development Program Somaxon submitted the NDA for SILENOR™ under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, which allows the company to rely on published literature reports or the FDA's findings of safety and efficacy for other formulations of doxepin hydrochloride that have previously been approved by the FDA. The NDA was submitted in accordance with the FDA's Electronic Common Technical Document (eCTD) specifications. The NDA includes all of the data from the company's clinical development program, including data from each of Somaxon's four Phase 3 clinical trials evaluating SILENOR™ for the treatment of insomnia. The following summarizes the results from these Phase 3 clinical trials: - In a clinical trial to evaluate SILENOR™ in the treatment of 229 adults with chronic insomnia in a sleep laboratory setting, SILENOR™ demonstrated a statistically significant improvement compared with placebo on the primary endpoint of Wake After Sleep Onset (WASO), as well as a range of secondary endpoints including Latency to Persistent Sleep (LPS) and Total Sleep Time (TST). - In a clinical trial to evaluate SILENOR™ in the treatment of 565 healthy adults experiencing transient insomnia in a sleep laboratory setting, SILENOR™ demonstrated a statistically significant improvement compared with placebo on the primary endpoint of LPS, as well as a range of secondary endpoints including WASO, TST and Latency to Sleep Onset (LSO). - In a clinical trial to evaluate SILENOR™ in the treatment of 255 elderly patients with primary sleep maintenance insomnia in an outpatient setting, SILENOR™ demonstrated a statistically significant improvement compared with placebo in the primary endpoint of subjective Total Sleep Time (sTST), as well as a range of secondary endpoints including subjective Wake After Sleep Onset and Sleep Quality. - In a clinical trial to evaluate long-term use of SILENOR™ in 240 elderly patients in both the sleep laboratory and outpatient settings, SILENOR™ demonstrated a statistically significant improvement compared with placebo in the primary endpoint of WASO, as well as a range of secondary endpoints including TST, Sleep Efficiency, sTST, and LSO. - The clinical trial results also demonstrated a favorable safety and tolerability profile for SILENOR™, with the overall incidence of adverse events comparable to placebo, a low discontinuation rate and no evidence of dependency, withdrawal, tolerance or amnesia. The most frequently reported adverse events across all of the Phase 3 clinical trials were somnolence, upper respiratory tract infection, sinusitis, nausea and hypertension; of these, somnolence was the only adverse event that was dose-related. The NDA submission also includes data from Somaxon's non-clinical development program, including the genotoxicity, reproductive toxicology and 26-week transgenic mouse carcinogenicity non-clinical studies of SILENOR™, which were initiated and completed based on a request from the FDA in May 2006. At that time, the FDA indicated that the data from the genotoxicity studies and reproductive toxicology studies should be included in the initial NDA submission. The FDA also indicated that depending on the outcome of the genotoxicity studies, it may be flexible as to the timing of the conduct of the requested carcinogenicity studies, including the potential that the data from those studies may be submitted as a post-NDA approval commitment. In September 2006, Somaxon completed the genotoxicity studies, and no signal indicative of genotoxicity was found in any of the assays. The company submitted the results to the FDA, and the FDA agreed with the company's assessment that SILENOR™ does not appear to have genotoxic potential. In February 2007, the FDA indicated that, unless other non-clinical data raise a concern, a complete assessment of the carcinogenic potential of SILENOR™ may not be needed prior to NDA approval. The FDA also indicated that it may accept the results of a shorter-term carcinogenicity study for approval of the NDA and allow the standard two-year carcinogenicity study to be completed as a post-NDA approval commitment. In May 2007, Somaxon received correspondence from the FDA which stated that the results of its 26-week transgenic mouse carcinogenicity study of SILENOR™ should be included as part of the initial NDA submission for SILENOR™. The company continues to plan to submit the results of the standard two-year carcinogenicity study as a post-approval commitment. Somaxon initiated that study, which is a two-year carcinogenicity study in rats, in August 2007. About Insomnia Approximately 70 million American adults are affected by insomnia - characterized by difficulty falling asleep, waking frequently during the night, waking too early and not being able to return to sleep, or waking up not feeling refreshed. Results from a 2005 National Sleep Foundation Sleep in America poll reported that respondents experienced the following insomnia symptoms: - 54% experience insomnia symptoms a few nights a week, - 32% awake often during the night (sleep maintenance), - 21% wake up too early and can not get back to sleep (premature final awakening), and - 21% have difficulty falling asleep (sleep onset). An estimated 20% to 40% of all adults complain of acute, or transient, insomnia, generally defined as a complaint lasting several days up to a couple of weeks, while 10% to 15% complain of chronic insomnia, generally defined as a complaint lasting approximately four weeks or longer. The negative health consequences of insomnia are becoming better understood. Studies have shown that insomnia lasting more than four weeks is associated with a wide range of adverse conditions, including mood disturbances, depression, difficulties with concentration and memory, and certain cardiovascular, pulmonary and gastrointestinal disorders. Chronic sleep deprivation has also been associated with an increased risk of diabetes and obesity. One study showed that when normal sleep was restricted by as little as two hours per night across two weeks, the affected person experienced a significant decrease in cognitive function that resulted in reaction time and other performance measures resembling those of a person who stayed up for 48 hours straight. About SILENOR™ SILENOR™ is a low-dose (1 mg, 3 mg, 6 mg) oral tablet formulation of doxepin hydrochloride that is patent protected for use in insomnia. Doxepin has been prescribed for more than 35 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day. At these higher doses used for these indications, doxepin is known to have a range of undesirable side effects, including anticholinergic and next-day residual effects. However, based upon the controlled clinical trials of SILENOR™ completed by Somaxon, the company believes that SILENOR™ will be well tolerated by patients. In addition, the FDA has indicated that it will recommend that SILENOR™ not be scheduled as a controlled substance. About Somaxon Pharmaceuticals, Inc. Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. For more information, please visit the company's web site at http://www.somaxon.com. Somaxon cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. For example, statements regarding the potential acceptance for filing or approval of the NDA for SILENOR™, the interpretation of the results of Somaxon's non-clinical studies and the FDA's agreement therewith, and the FDA's agreement that Somaxon may complete and submit the results of its two-year carcinogenicity study of SILENOR™ as a post-approval commitment are forward looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Somaxon that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Somaxon's business, including, without limitation, the potential for the FDA to require non-clinical, clinical or other requirements to support acceptance for filing of the NDA for SILENOR™, or the imposition of additional requirements to be completed before or after regulatory approval; Somaxon's ability to demonstrate to the satisfaction of the FDA that potential NDA approval of SILENOR™ is appropriate without standard, long-term carcinogenicity studies, given the context of completed trials and pending studies; the potential for SILENOR™ to receive regulatory approval for one or more indications and with a label that is consistent with Somaxon's patent protection on a timely basis or at all; the timing and results of non-clinical studies for SILENOR™, and the FDA's agreement with Somaxon's interpretation of such results; the potential to enter into and the terms of any strategic transaction relating to SILENOR™; the scope, validity and duration of patent protection and other intellectual property rights for SILENOR™; Somaxon's ability to have such patent protection provide exclusivity for SILENOR™; Somaxon's ability to operate its business without infringing the intellectual property rights of others; unexpected findings relating to SILENOR™ that could delay or prevent regulatory approval or commercialization, or that could result in recalls or product liability claims; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for SILENOR™; the market potential for insomnia, and Somaxon's ability to compete; Somaxon's ability to raise sufficient capital; and other risks detailed in Somaxon's prior press releases as well as in its periodic filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Somaxon undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934. Somaxon Pharmaceuticals
autism actos, hydrocodone m35b, joe dur, methadone and lortab on drug tests, buy meridia online, ic oxycodone effects, phentermine free consult overnight, california serzone attorney, soma mali, toronto soma liberal arts school 12:48 - 2008-Mar-25 - comments {0} - post commentWhat You Should Know About Lip AugmentationLip augmentation method is used to increase the size of the lips. This surgical procedure is being used world wide to enhance the beauty of lips. The upper and lower lip is treated alone in this method. The size of lips is changed by injecting collagen in the lips. The methods of lip augmentation are both temporary and permanent. The most common material which is injected in the lips is known as collagen. The collagen is obtained form the skin of the cow. The collagen obtained from the cows is purified in the laboratory. Collagen injections can cause allergy in some people. Before the cosmetic procedure a collagen sensitivity test should be performed on the patient. Collagen is injected in the dermal layer of the skin with the help of small needles. Collagen injection does not give long lasting results as after some time implant is absorbed by the body. Some physicians choose fat as an implant for the lips. Fat is harvested from another parts of the body and purified before injecting. Fat injections never cause allergic reactions as it is a human product. Some more form of injections which are used in this procedure are artecoll injections, autologen injections, dermalogen injections, fascia injections, hylaform injections and restylane injections. The recovery period is very short and depends on the method of surgery. For faster recovery patient should apply ice packs on the lips. Patient should not eat any thing first in 48 hours of post operative period. Patient is not allowed to smile and laugh for some hours after the procedure. If you want to have more information about Collagen Lip Injections then feel free to visit Lip Injections.
celebrex and regulatory issues, celexa versus prozac, dilantin seizure side effect, effexor venlafaxine side effects, class action suit ttp from lipitor, opium for pain, phentermine is it safe to, augment prozac with effexor xr, ramipril and potassium supplements, tamoxifen cardiac side effects 12:43 - 2008-Mar-19 - comments {0} - post commentCDC Study Reveals Adults May Not Get Enough Rest Or SleepAbout 10 percent of adults report not getting enough rest or sleep every day in the past month, according to a new four-state study released by the Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report. The data from the four states-Delaware, Hawaii, New York, and Rhode Island-may not reflect national trends. But an additional study conducted by CDC utilizing data from the National Health Interview Study indicated that across all age groups the percentage of adults who, on average, report sleeping six hours or less has increased from 1985 to 2006. Nationwide, an estimated 50 to 70 million people suffer from chronic sleep loss and sleep disorders. Sleep loss is associated with health problems, including obesity, depression, and certain risk behaviors, including cigarette smoking, physical inactivity, and heavy drinking. "It's important to better understand how sleep impacts people's overall health and the need to take steps to improve the sufficiency of their sleep," said Lela R. McKnight-Eily, Ph.D., the study's lead author and a behavioral scientist in CDC's Division of Adult and Community Health. "There are very few studies to assess and address sleep insufficiencies; therefore, more needs to done to better understand the problem and to develop effective sleep interventions." The study, "Perceived Insufficient Rest or Sleep--Four States, 2006," analyzed data from CDC's Behavioral Risk Factor Surveillance System (BRFSS) survey. Among the four states, the percentage of adults who reported not getting enough rest or sleep every day in the past 30 days ranged from 14 percent in Delaware to 8 percent in Hawaii. People concerned about chronic sleep loss should consult a physician for an assessment and possible treatment, such as behavioral or medical interventions, McKnight-Eily said. They can also try setting a regular sleep schedule and avoiding caffeine or other stimulants before bed, she said. Variation for insufficient rest and sleep may be due to occupational or lifestyle factors. The causes of sleep loss could include busy schedules or shift work; irregular sleep schedules; or lifestyle factors such as heavy family demands, late-night television watching and Internet use, or the use of caffeine and alcohol, according to a 2006 Institute of Medicine report. The National Sleep Foundation reports that most adults need 7-9 hours of sleep each night to feel fully rested while school children aged 5-12 years require 9-11 hours, and adolescents aged 11-17 years require 8.5-9.5 hours each night. The study also found that the prevalence of insufficient sleep decreased with age. An estimated 13.3 percent of adults aged 18-34 reported insufficient rest or sleep everyday in the past month compared to only 7.3 percent of adults ages 55 and older. While some studies have found sleep disturbance more prevalent among older adults, results from this study are consistent with other research that supports the idea that older adults (who are more likely to be retired) make fewer complaints regarding impaired sleep and adapt their perception of what encompasses sufficient sleep. In addition, the study showed that only one out of three (29.6 percent) adults said they did get enough rest or sleep every day in the past month. The MMWR report said the definitions of "enough" (sufficient) sleep and "rest," and responses to the survey question were subjective and were not measured or equated to reports of hours of sleep per night. The report said the analysis cannot be compared directly with studies measuring hours of sleep. The survey question also did not define or distinguish between "rest" and "sleep." The study comes just before National Sleep Awareness Week®, an annual campaign held in conjunction with Daylight Saving Time. For more information on National Sleep Awareness Week®, held March 3-9, please visit http://www.sleepfoundation.org. For more information on CDC's Sleep and Sleep Disorders Program, please visit http://www.cdc.gov/sleep. Centers for Disease Control and Prevention's
budeprion bupropion difference, nursing management for esomeprazole, glucophage and hot flashes, phone consultaion for hydrocodone, hyzaar sun exposure, federal government jobs and ritalin, artery tamoxifen heart, tramadol hcl sude effects, definition ultrams, yasmin aga 15:56 - 2008-Mar-18 - comments {0} - post comment |
Informationacetaminophen enzyme elevations hispanicsRecent Posts Weight loss pills - Lose weight with minimum effort Posted By : Smartess Chikwendu Are Cold Sores Contagious? Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia What You Should Know About Lip Augmentation CDC Study Reveals Adults May Not Get Enough Rest Or Sleep Links acetaminophen dextromethrophan doxylamine succinate acetaminophen dextromethorphan hbr acetaminophen diphenhydramine acetaminophen diphenhydramine hc acetaminophen diphenhydramine phenylephrine hc acetaminophen doctor acetaminophen dog acetaminophen dogs acetaminophen dosage 24 hours acetaminophen dosage chart acetaminophen dosage for dogs acetaminophen dosages acetaminophen dose for infants acetaminophen dosing reference acetaminophen drug classification acetaminophen dose lethal acetaminophen doseage acetaminophen dosing chart acetaminophen drug information acetaminophen drug taking test when acetaminophen during pregnancy acetaminophen effect on cholesterol acetaminophen effects hydrocodone side acetaminophen effects on liver acetaminophen epilim acetaminophen every 8 hrs for pain acetaminophen extra acetaminophen fact acetaminophen fda patient information acetaminophen fever in dogs acetaminophen flu acetaminophen for dogs acetaminophen formation acetaminophen found in cat food acetaminophen free pain medication acetaminophen functional groups acetaminophen geometry acetaminophen gout acetaminophen guaifenesin phenylephrine hcl acetaminophen hazard acetaminophen hcl par tramadol acetaminophen hepatotoxicity neurotransmitter net acetaminophen highs acetaminophen hplc analysis shimadzu acetaminophen hydrocodone 500 5 acetaminophen hydrocodone cause liver damage acetaminophen hydrocodone lortab acetaminophen ibuprofen acetaminophen ibuprofen differences acetaminophen ibuprofen interaction acetaminophen ibuprofen mix single dose acetaminophen ibuprofen together acetaminophen ibuprofin acetaminophen illagel n cat food acetaminophen in crabs acetaminophen in dogs acetaminophen in pet foods acetaminophen indications acetaminophen infant drops acetaminophen integration risk acetaminophen interaction with prozac acetaminophen intoxication and sodium sulfate acetaminophen isometheptene dichloralphenazone acetaminophen kidney insufficiency acetaminophen l405 acetaminophen law suits kansas acetaminophen lethal dose acetaminophen level less than 10 acetaminophen liver children acetaminophen liver damage repair acetaminophen liver enzymes hispanics elevations volunteers acetaminophen liver failure acid kidney |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
